Our gut contains a sleepless army, creating a hostile environment for pathogens, and helping to fortify our body’s immune defences. It may surprise you to learn that this army isn’t even human in nature, but is bacterial. The trillions of bacteria that naturally live in our gut, known as the gut microbiota, form an important component of our overall immunity against infectious disease. While bacteria can also cause disease, beneficial bacteria naturally colonise available spaces in our body, such as the gut, and play a key role in our immunity and physiology. Research conducted by Prof. Nelson Gekara of Stockholm University in Sweden and colleagues has revealed that these microscopic organisms play a crucial role in protecting us from viral infections, even in organs that are unconnected to the gut. Their study, published in the journal Immunity, uncovers a fascinating link between the gut microbiota and our body’s ability to fight viruses, offering new insights into immune function and the unintended consequences of antibiotic use.

Cancer is a daunting healthcare challenge, and is still affecting millions worldwide, despite the enormous research resources that have been directed at finding effective treatments over the past decades. Many anti-cancer treatments remain poorly specific for the tumours they are intended to treat, and often suffer from modest efficacy and serious off-target effects. Part of the problem is the inherent variability between many tumours and their resulting unpredictable responses to standard chemotherapy. However, the latest advancements in precision oncology may be the start of a new paradigm, potentially providing targeted therapeutic payloads that can successfully address the specific and unique issues underlying a given patient’s cancer. Researchers such as Prof. Diana Jaalouk and her colleagues at the American University of Beirut in Lebanon are pioneering innovative tools that are changing the way we understand and treat this complex disease. Two remarkable recent technologies, CRISPR-Cas9 and PROteolysis TArgeting Chimeras (or PROTACs for short), are at the forefront of this precision revolution. While distinct in their approach, these tools share a common goal: targeting cancer with precision and minimizing harm to healthy cells. Together, they are set to reshape the therapeutic landscape.